Literature DB >> 11793110

Plasma levels of advanced glycation end products in children with renal disease.

K Sebeková1, L Podracká, P Blazícek, D Syrová, A Heidland, R Schinzel.   

Abstract

In adults, advanced glycation end products (AGEs) rise slowly in tissues and circulation during aging, and accumulate at an accelerated rate both in diabetes and chronic renal insufficiency (CRI). We aimed to investigate the pattern of AGE accumulation in children/adolescents with CRI and on renal replacement therapy by dialysis and transplantation. Concentrations of fluorescent AGEs, carboxymethyllysine (CML) and lipofuscin-like substance (LFLS, a marker of lipid peroxidation) were followed. Data were obtained from 11 CRI patients on conservative treatment (age 12.6+/-1.7 years, serum creatinine: 205.7+/-17.5 micromol/l), ten patients on renal replacement therapy with dialysis (13.6+/-1.7 years, 698.2+/-48.9 micromol/l) and nine patients after kidney transplantation (15.9+/-1.1 years, 115.9+/-12.0 micromol/l) and comparison made with the data from 28 healthy controls (11.8+/-8.2 years, 44.1+/-8.2 micromol/l). In controls, an age-dependent rise of fluorescent AGE and CML levels was observed. In the CRI group, fluorescent AGEs [0.38+/-0.03x105 arbitrary units (AU)] and CML (369+/-26 ng/ml) concentrations were doubled compared with controls (0.16+/-0.03x105 AU and 189+/-42 ng/ml, respectively) and even higher levels were revealed in dialyzed patients (0.80+/-0.05x105 AU; 650+/-94 ng/ml). Successful kidney transplantation significantly reduced but did not normalize fluorescent AGE levels (0.39+/-0.03 x105 AU), while the decline in CML levels (550+/-47 ng/ml) was insignificant. Plasma LFLS was elevated in CRI (19.6+/- 1.7 AU) and was even higher in dialyzed children (32.0+/-5.3 AU) compared with healthy controls (7.1+/- 1.4 AU). Kidney transplantation did not normalize LFLS levels (20.3+/-5.3 AU), pointing to persistently enhanced lipid peroxidation. Our study provides the first data on enhanced fluorescent AGEs and CML levels in children/adolescents with CRI and on dialysis. Successful renal transplantation decreased but did not normalize AGE levels, probably because of still-impaired renal function with enhanced oxidative stress, as well as the influence of immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11793110     DOI: 10.1007/s004670100038

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  12 in total

1.  Circulating Advanced Glycation Endproducts and Long-Term Risk of Cardiovascular Mortality in Kidney Transplant Recipients.

Authors:  Camilo G Sotomayor; António W Gomes-Neto; Marco van Londen; Rijk O B Gans; Ilja M Nolte; Stefan P Berger; Gerjan J Navis; Ramón Rodrigo; Henri G D Leuvenink; Casper G Schalkwijk; Stephan J L Bakker
Journal:  Clin J Am Soc Nephrol       Date:  2019-09-17       Impact factor: 8.237

Review 2.  Glycation free adduct accumulation in renal disease: the new AGE.

Authors:  Paul J Thornalley
Journal:  Pediatr Nephrol       Date:  2005-08-24       Impact factor: 3.714

3.  Effect of non-enzymatic glycation on cystatin: a spectroscopic study.

Authors:  Sheraz Ahmad Bhat; Aamir Sohail; Azad Alam Siddiqui; Bilqees Bano
Journal:  J Fluoresc       Date:  2014-05-02       Impact factor: 2.217

4.  Prognostic potential and tumor growth-inhibiting effect of plasma advanced glycation end products in non-small cell lung carcinoma.

Authors:  Babett Bartling; Hans-Stefan Hofmann; Antonia Sohst; Yvonne Hatzky; Veronika Somoza; Rolf-Edgar Silber; Andreas Simm
Journal:  Mol Med       Date:  2011-05-24       Impact factor: 6.354

5.  Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation.

Authors:  A Heidland; K Sebeková; A Frangiosa; L S De Santo; M Cirillo; F Rossi; M Cotrufo; A Perna; A Klassen; R Schinzel; N G De Santo
Journal:  Heart       Date:  2004-11       Impact factor: 5.994

6.  Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: a new insight into selective nitrergic neuropathy in diabetes.

Authors:  S Cellek; W Qu; A M Schmidt; S Moncada
Journal:  Diabetologia       Date:  2003-12-16       Impact factor: 10.122

Review 7.  Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease.

Authors:  Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2008-12-13       Impact factor: 3.714

8.  A developmental nephron deficit in rats is associated with increased susceptibility to a secondary renal injury due to advanced glycation end-products.

Authors:  M A Zimanyi; K M Denton; J M Forbes; V Thallas-Bonke; M C Thomas; F Poon; M J Black
Journal:  Diabetologia       Date:  2006-02-23       Impact factor: 10.122

9.  Gold Nanoparticle-Based Detection of Low Molecular Weight AGEs from In Vitro Glycated Haemoglobin A0 Samples.

Authors:  A Asha Madhavan; S Juneja; P Sen; R Ghosh Moulick; J Bhattacharya
Journal:  Nanoscale Res Lett       Date:  2018-12-04       Impact factor: 4.703

Review 10.  The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases.

Authors:  Mieke Steenbeke; Reinhart Speeckaert; Stéphanie Desmedt; Griet Glorieux; Joris R Delanghe; Marijn M Speeckaert
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.